In a report released today, Michael Petusky from Barrington maintained a Buy rating on Henry Schein (NASDAQ: HSIC), with a price target of $92. The company’s shares opened today at $80.64.
Petusky wrote:
“We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur before year end. In addition, the guidance does not factor in any future M&A activity.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 16.3% and a 64.4% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $81.88 average price target, representing a 1.5% upside. In a report released today, Robert W. Baird also reiterated a Buy rating on the stock with a $90 price target.
.
See today’s analyst top recommended stocks >>
Henry Schein’s market cap is currently $12.66B and has a P/E ratio of 30.50. The company has a Price to Book ratio of 4.36.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments.
